Literature DB >> 24051864

Increased risk of cirrhosis and its decompensation in chronic hepatitis B patients with newly diagnosed diabetes: a nationwide cohort study.

Yi-Wen Huang1, Ting-Chuan Wang, Shih-Chang Lin, Han-Yu Chang, Ding-Shinn Chen, Jui-Ting Hu, Sien-Sing Yang, Jia-Horng Kao.   

Abstract

BACKGROUND: The impact of diabetes on cirrhosis, its decompensation, and their time relationship in patients with chronic hepatitis B (CHB) remain unclear.
METHODS: We conducted a nationwide cohort study by using the Taiwanese National Health Insurance Research Database, which was comprised of data from >99% of the entire population. Among 1 million randomly sampled enrollees, 14 523 adult CHB patients were identified from 1997 to 2009. Diabetes was defined as newly diagnosed in CHB patients who were given the diagnosis in the years 1998-2001 but not in 1996-1997 and with physician visits of at least twice per year. The cohorts of CHB with newly diagnosed diabetes (n = 351) and without diabetes (n = 7886) were followed up from the diagnosis of diabetes and from 2000 in the patients without diabetes until development of cirrhosis or its decompensation, withdrawal from insurance, or December 2009.
RESULTS: Kaplan-Meier survival analysis showed a significantly higher cumulative incidence of cirrhosis (relative risk [RR] = 3.43; 95% confidence interval [CI], 2.62-4.49; P < .001, log-rank test) and decompensated cirrhosis (RR = 4.11; 95% CI, 2.95-5.70; P < .001, log-rank test) among patients with newly developed diabetes compared with those without diabetes. After adjustment for age, sex, CHB treatment, hepatocellular carcinoma, and comorbidity index by Cox proportional hazards model, diabetes was still an independent predictor for cirrhosis (hazard ratio [HR] = 2.015; 95% CI, 1.393-2.915; P < .001) and its decompensation (HR = 1.792; 95% CI, 1.192-2.695; P = .005).
CONCLUSIONS: Patients with CHB who develop diabetes are at an increased risk of liver cirrhosis and its decompensation over time.

Entities:  

Keywords:  comorbidity; database; decompensated cirrhosis; population; time-relationship

Mesh:

Year:  2013        PMID: 24051864     DOI: 10.1093/cid/cit603

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  31 in total

1.  Statins Reduce the Risk of Cirrhosis and Its Decompensation in Chronic Hepatitis B Patients: A Nationwide Cohort Study.

Authors:  Yi-Wen Huang; Chia-Long Lee; Sien-Sing Yang; Szu-Chieh Fu; Yun-Yi Chen; Ting-Chuan Wang; Jui-Ting Hu; Ding-Shinn Chen
Journal:  Am J Gastroenterol       Date:  2016-05-10       Impact factor: 10.864

Review 2.  Association between hepatitis B and metabolic syndrome: Current state of the art.

Authors:  Peter Jarcuska; Sylvia Drazilova; Jan Fedacko; Daniel Pella; Martin Janicko
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

3.  Effect of Metabolic Syndrome on the Clinical Outcomes of Chronic Hepatitis B Patients with Nucleos(t)ide Analogues Treatment.

Authors:  Nam Hee Kim; Yong Kyun Cho; Byung Ik Kim; Hong Joo Kim
Journal:  Dig Dis Sci       Date:  2018-06-12       Impact factor: 3.199

4.  Hepatic arteriolosclerosis: a small-vessel complication of diabetes and hypertension.

Authors:  Maya Balakrishnan; Guadalupe Garcia-Tsao; Yanghong Deng; Maria Ciarleglio; Dhanpat Jain
Journal:  Am J Surg Pathol       Date:  2015-07       Impact factor: 6.394

Review 5.  Current Concepts in Diabetes Mellitus and Chronic Liver Disease: Clinical Outcomes, Hepatitis C Virus Association, and Therapy.

Authors:  Diego García-Compeán; José Alberto González-González; Fernando Javier Lavalle-González; Emmanuel Irineo González-Moreno; Jesús Zacarías Villarreal-Pérez; Héctor J Maldonado-Garza
Journal:  Dig Dis Sci       Date:  2016-02       Impact factor: 3.199

6.  Factors associated with high alanine aminotransferase (ALT) and cirrhosis in people living with HIV on combination antiretroviral treatment (cART) in the Asia-Pacific.

Authors:  Dhanushi Rupasinghe; Jun Yong Choi; Evy Yunihastuti; Sasisopin Kiertiburanakul; Jeremy Ross; Penh Sun Ly; Romanee Chaiwarith; Cuong Duy Do; Yu-Jiun Chan; Nagalingeswaran Kumarasamy; Anchalee Avihingsanon; Adeeba Kamarulzaman; Suwimon Khusuwan; Fujie Zhang; Man Po Lee; Kinh Van Nguyen; Tuti Parwati Merati; Sashikala Sangle; Ng Oon Tek; Junko Tanuma; Rossana Ditangco; Benedict Lim Heng Sim; Sanjay Pujari; Awachana Jiamsakul
Journal:  J Med Virol       Date:  2022-08-15       Impact factor: 20.693

7.  Association between diabetes mellitus and cirrhosis mortality: the Singapore Chinese Health Study.

Authors:  George Boon-Bee Goh; An Pan; Wan-Cheng Chow; Jian-Min Yuan; Woon-Puay Koh
Journal:  Liver Int       Date:  2016-09-16       Impact factor: 5.828

8.  Propranolol use in patients with cirrhosis and refractory ascites: A nationwide study.

Authors:  Yen-Chun Chen; Yun-Da Li; Chia-Ming Lu; Wei-Chun Huang; Sung-Shuo Kao; Wen-Chi Chen
Journal:  Saudi J Gastroenterol       Date:  2022 Mar-Apr       Impact factor: 2.485

9.  Characterization of an age-response relationship to GSK's recombinant hepatitis B vaccine in healthy adults: An integrated analysis.

Authors:  Olivier Van Der Meeren; Priya Crasta; Brigitte Cheuvart; Marc De Ridder
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

10.  MicroRNA gene polymorphisms and environmental factors increase patient susceptibility to hepatocellular carcinoma.

Authors:  Yin-Hung Chu; Ming-Ju Hsieh; Hui-Ling Chiou; Yi-Sheng Liou; Chen-Chieh Yang; Shun-Fa Yang; Wu-Hsien Kuo
Journal:  PLoS One       Date:  2014-02-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.